TransCode Therapeutics (RNAZ) announced that its Board of Directors has approved a 1-for-28 reverse stock split. The reverse stock split was approved by TransCode’s stockholders on May 2, and is intended to increase the per share trading price of the company’s common stock to enable the company to satisfy the minimum bid price requirement for continued listing on the Nasdaq Capital Market. The effective date of the reverse stock split has not yet been determined and will be announced by the company at least two business days prior to its implementation.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNAZ:
- TransCode Therapeutics (NASDAQ: RNAZ) Advances Phase 1a Trial of RNA Cancer Therapy TTX-MC138
- Transcode Therapeutics’ TTX-MC138 shows no toxicities in Phase 1a cancer trial
- Transcode Therapeutics price target lowered to $10 from $20 at H.C. Wainwright
- TransCode Therapeutics Delays Annual Report Filing
- Transcode Therapeutics begins dosing in fourth cohort of Phase 1 cancer trial